Table 2. Surveillance, Epidemiology, and End Results–Medicare Molecular Cohort: Multivariable-Adjusted Cox Proportional Hazards Regression Model of All-Cause Mortality (n = 130)a.
| Parameter | All-cause mortality, HR (95% CI) |
|---|---|
| Tumor screening factors | |
| Symptomatic tumor | 2.49 (1.19-5.20) |
| Stage N2 or greater tumor | 3.43 (0.72-16.3) |
| Stage T2 vs T1 tumor | 4.09 (1.79-9.34) |
| High grade vs low/intermediate grade tumor | 0.87 (0.39-1.96) |
| Sociodemographic factors | |
| Aged 71-75 vs 66-70 y | 2.42 (1.24-4.73) |
| Patient zip code | |
| Highest quartile: Black race | 0.95 (0.48-1.89) |
| Highest quartile: less than high school education | 5.17 (2.12-12.60) |
| Highest quartile: low-income household | 1.21 (0.53-2.74) |
| Married | 1.64 (0.83-3.26) |
| Lives in metropolitan region | 0.84 (0.40-1.73) |
| Lives in rural area | 0.76 (0.18-3.26) |
| Hawaii tumor registry | 0.74 (0.23-2.40) |
| Clinical factors | |
| Diagnosed 2000 or later | 1.16 (0.55-2.47) |
| PGR borderline/negative/missing vs positive | 2.90 (1.05-7.98) |
| Subtype luminal B vs luminal A | 1.17 (0.53-2.57) |
| Comorbidity score | |
| 0 | 1 [Reference] |
| 1 | 1.29 (0.54-3.07) |
| ≥2 | 9.94 (3.16-31.30) |
| Gene signatures | |
| ESR1 signature | 0.82 (0.51-1.32) |
| PGR signature | 0.82 (0.67-1.00) |
| ERBB2 signature | 0.54 (0.30-0.95) |
| FOXA1 signature | 0.98 (0.38-2.54) |
| Androgen receptor signature | 0.23 (0.12-0.45) |
| IDO1 signature | 0.80 (0.42-1.52) |
| PDL1 signature | 0.90 (0.39-2.03) |
| PDL2 signature | 1.24 (0.54-2.86) |
| PD1 signature | 1.63 (0.79-3.36) |
| B7_H3 signature | 0.95 (0.33-2.76) |
| TIGIT | 1.93 (0.96-3.87) |
| TGFβ signature | 5.61 (1.90-16.60) |
| Endothelial cells signature | 1.04 (0.40-2.75) |
| Macrophage signature | 0.20 (0.09-0.45) |
| Mast cells signature | 0.93 (0.69-1.27) |
| Treg signature | 0.41 (0.21-0.79) |
| BC proliferation signature | 1.06 (0.85-1.34) |
| BC stroma signature | 0.75 (0.43-1.32) |
| APM signature | 1.24 (0.73-2.12) |
| BC cytotoxicity signature | 0.63 (0.44-0.89) |
| BC apoptosis signature | 1.09 (0.88-1.34) |
| BC inflammatory chemokines | 1.00 (0.68-1.48) |
| p53 Dysregulation | 2.15 (1.20-3.86) |
| ER signaling signature | 1.11 (0.60-2.07) |
| Differentiation signature | 2.09 (0.65-6.65) |
| BRCAness signatureb | 0.54 (0.28-1.03) |
Abbreviations: APM, antigen processing machinery; BC, breast cancer; ER, estrogen receptor; HR, hazard ratio; PGR, progesterone receptor; TGFβ, transforming growth factor β.
a
Colinear signatures (variance inflation factor of >10) were dropped, including claudin low, tumor in situ, CD8 T cells, and cytotoxic T cells.
b
Defined by the Breast Cancer 360 NanoString panel.